Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03823040
Recruitment Status : Completed
First Posted : January 30, 2019
Last Update Posted : January 30, 2019
Sponsor:
Information provided by (Responsible Party):
Heba Mansour, Minia University

Brief Summary:
Clinical study for the developed oxiconazole nitrate solid lipid nanoparticles (SLNs) gel system compared to the corresponding marketed product was conducted on 28 patients with different types of tinea fungal infection.

Condition or disease Intervention/treatment Phase
Tinea Drug: Oxiconazole Nitrate Cream 1% Drug: Oxiconazole nitrate SLNs loaded gel. Phase 1

Detailed Description:

The clinical work has been carried out in accordance with The Code of Ethics of the World Medical Association for experiments involving humans. The study was conducted on 28 patients (12 to 50 years old) with tinea of different types attending the dermatology department outpatient clinic of Minia University Hospital. Local institutional review board approval was obtained for this study (ethical approval number is 23/12). Pregnant females and patients with Immunocompromising disease,open wounds and psychological disorders were excluded. Patients were subjected to skin irritation test by applying gel on an area of 2 square inch to the back of hand. Then, examination for the presence of lesion or irritation was conducted. The patients divided into two groups of 14 patients each. Tinox® group was male patients from 12 to 43 years old. The included cases were 5 tinea pedis, 9 tinea versicolor. Oxiconazole nitrate SLNs loaded gel group was 13 males and one female from17 to 50 years old. The included cases were 3 tinea pedis, 8 tinea versicolor, 3 tinea circinate. An informed consent has been obtained from all patients enrolled in the study for photography and treatment. History, general local examination and laboratory investigation for all patients were conducted.The patients were clinically examined after determining the type of infection. Tinox® group was treated with Tinox® cream 1 % while oxiconazole nitrate SLNs loaded gel group was treated with the oxiconazole nitrate SLNs-loaded gel. Treatment was performed by rubbing the cream or gel twice daily for two/ four weeks according to different types of tinea. Patients were advised to avoid sun exposure between 10 am and 4 pm and avoid removal of the applied dose during the period of follow up, the clinical improvement of the patients and length of treatment was assessed according to quartile grading scale patient satisfaction. It was rated by the patient and the physician as excellent, good, fair and poor according to the following criteria. Excellent: both the patient and the physician agreed that the result was satisfactory. Good: the result although acceptable was not quite up to expectation of the patient, but the physicians were pleased with the outcome. Fair: the improvement was evaluated by both the patient and the physician to be less than expected but still with same improvement. Poor: unsatisfactory results to the patient and /or the physician. All adverse effects were checked during study.High resolution digital photographs were taken for lesions of all patients using identical camera folder setting before starting and one-month post treatment. Clinical improvement was evaluated by physicians through comparing photographs. The criteria for evaluations using a quartile grading scale was: 0=no improvement. 1=mild (percent improvement, less than 25%), 2=moderate (percent improvement 25-49%), 3=good (percent improvement 50-74%), 4=excellent (percent improvement more than 75%). In addition, a patient satisfaction score was rated using the following scale, A. not satisfied, B. somewhat satisfied, C. highly satisfied.

Skin scrapes were taken from each group before and after treatment. All skin scrapes were routinely processed by potassium hydroxide 20% to be examined for presence of fungal elements. A built-in camera and a light microscope were used to photograph and examine the sectioned skin areas.

IBM SPSS® ( International business machine statistical Package for the Social Sciences (version 22, USA) was utilised for data analysis. The acceptability of the tested formulations was assessed using the chi-square test, P ≤ 0.05 was considered statistically significant. All the results were presented as the mean ± standard deviation (SD).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Oxiconazole Nitrate Solid Lipid Nanoparticles : Formulation, In-vitro Characterization and Clinical Assessment of An Analogous Loaded Carbopol Gel
Actual Study Start Date : July 16, 2018
Actual Primary Completion Date : December 23, 2018
Actual Study Completion Date : December 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tinea Infections

Arm Intervention/treatment
Active Comparator: Tinox® group
Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
Drug: Oxiconazole Nitrate Cream 1%
Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
Other Name: Tinox® cream 1 %

Experimental: Oxiconazole nitrate SLNs loaded gel group
13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
Drug: Oxiconazole nitrate SLNs loaded gel.
Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
Other Name: Developed SLNs gel




Primary Outcome Measures :
  1. Measurement of clinical improvement using quartile grading scale patient satisfaction [ Time Frame: one month ]
    the clinical improvement of the patients was assessed according to quartile grading scale patient satisfaction. It was rated by the patient and the physician as excellent, good, fair and poor according to the following criteria. Excellent: both the patient and the physician agreed that the result was satisfactory. Good: the result although acceptable was not quite up to expectation of the patient, but the physicians were pleased with the outcome. Fair: the improvement was evaluated by both the patient and the physician to be less than expected but still with same improvement. Poor: unsatisfactory results to the patient and /or the physician. All adverse effects were checked during study.


Secondary Outcome Measures :
  1. Microscopical examination of skin scrapes for detection of fungal elements [ Time Frame: one month ]
    Skin scrapes were taken from each group before and after treatment. All skin scrapes were routinely processed by potassium hydroxide 20% to be examined for presence of fungal elements. A built-in camera and a light microscope were used to photograph and examine the sectioned skin areas.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with different types of tine infection

Exclusion Criteria:

  • Pregnant females and patients with Immunocompromising disease, open wounds and psychological disorders were excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03823040


Locations
Layout table for location information
Egypt
Minia University Hospital,dermatology department, out patient clinic
Minya, Egypt, 61519
Sponsors and Collaborators
Minia University
Investigators
Layout table for investigator information
Study Director: Heba F Mansour, Ph.D Associate professor of Pharmaceutics, Faculty of Pharmacy, Minia and Deray University, Minia, Egypt.

Layout table for additonal information
Responsible Party: Heba Mansour, Assistant professor of pharmaceutics, Faculty of Pharmacy, Minia University, Minia University
ClinicalTrials.gov Identifier: NCT03823040     History of Changes
Other Study ID Numbers: OXIHebaSLNs
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: January 30, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Oxiconazole
Antifungal Agents
Anti-Infective Agents